Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.

doi:10.1016/j.jmoldx.2020.11.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.

The Journal of molecular diagnostics : JMD - 1 Mar 2021

Momeni-Boroujeni Amir, Salazar Paulo, Zheng Tao, Mensah Nana, Rijo Ivelise, Dogan Snjezana, Yao JinYuan, Moung Christine, Vanderbilt Chad, Benhamida Jamal, Chang Jason, Travis William, Rekhtman Natasha, Ladanyi Marc, Nafa Khedoudja, Arcila Maria E

Abstract excerpt

Mutations in the epidermal growth factor receptor (EGFR) are the most common targetable alterations in lung adenocarcinoma. To facilitate rapid testing, the Idylla EGFR assay was incorporated as a screening method before next-generation sequencing (NGS). Validation and experience using an in-house developed analysis pipeline, enhanced with a manual review algorithm is described. Results are compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Data Analysis

Share to ErbB Receptors

Share to High-Throughput Nucleotide Sequencing

Share to Nucleic Acid Amplification Techniques

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Share to Workflow

Source

Open in PubMed Open full text

Identifiers

PMID: 33346146
DOI: 10.1016/j.jmoldx.2020.11.009
PMCID: PMC7919857

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.PMID 33346146Read ↗

Rapid clinical mutational testing of KRAS, BRAF and EGFR: a prospective comparative analysis of the Idylla technique with high-throughput next-generation sequencingSemantic proximity Read ↗

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day.Semantic proximity Read ↗

Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples.Semantic proximity Read ↗

Use of the Idylla EGFR Mutation Test for Variant Detection in Non-Small Cell Lung Cancer Samples.Semantic proximity Read ↗

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung CancerSemantic proximity Read ↗

Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.Semantic proximity Read ↗

Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.Semantic proximity Read ↗

Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Rapid EGFR evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform.Semantic proximity Read ↗

Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations.Semantic proximity Read ↗

Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.